Literature DB >> 23298491

IL-18 level in patients undergoing coronary artery bypass grafting surgery or valve replacement: which link with epicardial fat depot?

E Dozio1, G Dogliotti, A E Malavazos, F Bandera, G Cassetti, E Vianello, R Zelaschi, A Barassi, G Pellissero, U Solimene, L Morricone, A Sigruener, V Tarabin, G Schmitz, L Menicanti, M M Corsi Romanelli.   

Abstract

Interleukin-18 (IL-18) is a member of the interleukin-1 family of cytokines produced constitutively by different cell types and by adipose tissue. Due to the link between obesity, inflammation and cardiovascular diseases, we aimed to measure IL-18 circulating level in patients undergoing open-heart surgery both for elective coronary artery bypass grafting (CABG) or for valve replacement (VR), and we also evaluated whether epicardial adipose tissue (EAT) depot may be a potential source of IL-18. Circulating IL-18 protein was quantified by enzyme-linked immunosorbent assay. IL-18, IL-18 receptor 1 (IL-18 R1) and IL-18 receptor accessory protein (IL-18-RAP) gene expression in EAT depot were evaluated by one colour microarray platform. EAT thickness was measured by echocardiography. In this study we found that all cardiovascular patients (CABG and VR) have increased circulating IL-18 level compared to healthy control subjects (p < 0.0001), but no statistical significant difference was observed between CABG and VR groups (p = 0.35). A great increase in the gene expression of IL-18 (p < 0.05), IL-18 R1 (p < 0.01) and IL-18 RAP (p < 0.001) was observed in EAT samples obtained from CABG vs VR patients. In conclusion, CABG and VR patients had similar increased level of circulating IL-18 protein, but in EAT depots isolated from CABG gene expression of IL-18, IL-18 R1 and IL-18-RAP resulted higher than in VR patients. Future investigation on local IL-18 protein production, its autocrine-paracrine effect and its correlation with plasmatic IL-18 level could give more information on the relationship between IL-18 and coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23298491     DOI: 10.1177/039463201202500418

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  5 in total

1.  Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women.

Authors:  Elena Dozio; Silvia Briganti; Alessandra Delnevo; Elena Vianello; Federica Ermetici; Francesco Secchi; Francesco Sardanelli; Lelio Morricone; Alexis E Malavazos; Massimiliano M Corsi Romanelli
Journal:  Eur J Nutr       Date:  2016-08-13       Impact factor: 5.614

2.  Interleukin-15 and soluble interleukin-15 receptor α in coronary artery disease patients: association with epicardial fat and indices of adipose tissue distribution.

Authors:  Elena Dozio; Alexis Elias Malavazos; Elena Vianello; Silvia Briganti; Giada Dogliotti; Francesco Bandera; Francesca Giacomazzi; Serenella Castelvecchio; Lorenzo Menicanti; Alexander Sigrüener; Gerd Schmitz; Massimiliano Marco Corsi Romanelli
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

3.  Expression of the Receptor for Advanced Glycation End Products in Epicardial Fat: Link with Tissue Thickness and Local Insulin Resistance in Coronary Artery Disease.

Authors:  Elena Dozio; Elena Vianello; Silvia Briganti; John Lamont; Lorenza Tacchini; Gerd Schmitz; Massimiliano Marco Corsi Romanelli
Journal:  J Diabetes Res       Date:  2015-12-14       Impact factor: 4.011

Review 4.  Transcriptome and Molecular Endocrinology Aspects of Epicardial Adipose Tissue in Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Zhila Maghbooli; Arash Hossein-Nezhad
Journal:  Biomed Res Int       Date:  2015-11-09       Impact factor: 3.411

5.  Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health.

Authors:  Elena Dozio; Elena Vianello; Clementina Sitzia; Federico Ambrogi; Stefano Benedini; Silvia Gorini; Benedetta Rampoldi; Roberta Rigolini; Lorenza Tacchini; Massimiliano Marco Corsi Romanelli
Journal:  J Clin Med       Date:  2020-02-06       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.